Prøve GULL - Gratis
Prime Snippets
PRIME Magazine
|Oct - Nov 2017
Latest medical news in brief
-
KOREAN START-UP SKY LABS SELECTED AS ONE OF THE WINNERS FOR BAYER GLOBAL GRANTS4APPS ACCELERATOR 2017
Sky Labs, a Korean start-up developing a subminiature ring-type atrial fibrillation (AF) diagnosis device ‘CART’ was selected as one of the winners along with three other digital health start-ups from United Kingdom and USA in the G4A Accelerator 2017 program, which fosters digital innovation in healthcare and supports start-up companies. Bayer received more than 450 digital health-related applications from 61 countries for this year, and applications from the US, Germany, Brazil and UK were extremely strong this year. This is also the second consecutive year that a Korean start-up has selected as one of the winners.
Sky Labs has been developing a ring-type device for accurate diagnosis and customized management of atrial fibrillation (AF), called CART (Cardio Tracker). AF is a chronic disease that affects one out of four people in their 40s or older, and may cause a stroke from which more than half of the patients die.
The winners will each receive financial support of EUR 50,000, mentoring and coaching by Bayer employees and external experts in Berlin to advance their digital health projects in areas, such as medical adherence, endometriosis, atrial fibrillation, deep vein thrombosis and ultrasound diagnostics until late November. Bayer senior managers and external experts will mentor and support the start-ups in further developing their business models and products during that time.
STUDY FINDS WOMEN’S BRAINS ARE FAR MORE ACTIVE THAN MEN’S
Denne historien er fra Oct - Nov 2017-utgaven av PRIME Magazine.
Abonner på Magzter GOLD for å få tilgang til tusenvis av kuraterte premiumhistorier og over 9000 magasiner og aviser.
Allerede abonnent? Logg på
FLERE HISTORIER FRA PRIME Magazine
PRIME Singapore
Living Large
The Illusion of Space in Small Homes
9 mins
February - March 2026
PRIME Singapore
Fend Off the Flames
Fire Safety Knowledge That Can Save Lives
7 mins
February - March 2026
PRIME Singapore
The World in Numbers
How Data Analytics Shapes Modern Decision-Making
14 mins
February - March 2026
PRIME Singapore
Thunder Struck
Chris Hemsworth: From God of Thunder to Hollywood Deity
29 mins
February - March 2026
PRIME Singapore
Ingesting Inflammation
Why Everyone is Talking About Anti-Inflammatory Diets
12 mins
February - March 2026
PRIME Singapore
Inked Later
Why More People Are Getting Tattoos After 40
7 mins
February - March 2026
PRIME Singapore
STUDY CONFIRMS ONE MONTH OF NO ALCOHOL MAKES REAL DIFFERENCE TO HEALTH
In 2013, Alcohol Change UK started the “Dry January” campaign, where people could commit to abstaining from drinking alcohol for the entire month.
2 mins
February - March 2026
PRIME Singapore
CERTAIN CHANGES IN DRIVING PATTERNS MAY POINT TO COGNITIVE DECLINE, DEMENTIA
Individuals with cognitive impairment are at a two-to five-fold increased risk of being involved in motor accidents, highlighting the deterioration of driving skills with a decline in cognitive function. A recent study published in Neurology suggests that changes in daily driving patterns recorded using a vehicle datalogger could reliably distinguish individuals with mild cognitive impairment (MCI) from those with normal cognition. The study’s findings suggest that data collected by vehicle data loggers could potentially be used in the early identification of individuals at risk of a motor crash or those with cognitive impairment, prior to in-person cognitive assessments or brain imaging scans. Driving data patterns could also serve as a tool to assess the effectiveness of interventions for treating cognitive impairment.
2 mins
February - March 2026
PRIME Singapore
LIFT ME UP
Volformer: The Rejuvenation Protocol Combining Precision Ultrasound and Volumetric RF
4 mins
February - March 2026
PRIME Singapore
TARGETING IDO1 FOR CANCER: NOVEL DEGRADERS SHOW PROMISE IN PRECLINICAL STUDIES
Cancer cells employ a variety of strategies to evade the immune system, and modern immunotherapies aim precisely at these escape mechanisms. However, such therapies are not always successful. A research team from the Max Planck Institute for Molecular Physiology in Dortmund and the AITHYRA Institute in Vienna has now developed a new class of compounds that specifically target and destroy the enzyme IDO1 – a key molecular switch that tumours use to suppress immune responses. They were also able to show that iDegs (IDO1 degraders) inhibit tumour growth in mice with SKOV-3 tumours, thereby prolonging survival time. This approach could markedly enhance the efficacy of existing immunotherapies and open new avenues in the fight against cancer. The new research was published in the journal Nature.
3 mins
February - March 2026
Translate
Change font size

